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Background
HIV-1 specific T cell responses induced by the MRKAd5
HIV-1 gag/pol/nef vaccine are highly variable, and human
genetic variation is likely to play a role in the inter-indi-
vidual differences. Contemporary genomic analyses make
it possible to comprehensively assess associations of com-
mon genetic variants with phenotypes. We here combine
whole-genome genotyping and HLA Class I typing results
to provide a global survey of the host mechanisms associ-
ated with variability in T cell responses to the vaccine.
Methods
All male vaccinees who were HIV seronegative 4 weeks
after the 2nd vaccination (week 8) were included. Geno-
typing data were obtained using Human 1 M BeadChips.
IFN-γ ELISpot assays using Gag, Pol and Nef peptide pools
were run on PBMCs collected at week 8. Positive
responses were analyzed in regression models including
age and eigenstrat values as covariates. Only Gag
responses and the sum of Gag/Pol/Nef responses were
considered, because preliminary data indicate that those
measures may associate with HIV viral load in infected
vaccinees.
Results
792 individuals had complete results. No genetic variant
reached genome-wide significance. However, the strong-
est determinants of Gag responses (p = 1E-06) were
observed in the MHC region. We therefore also tested
individual HLA alleles: B*2705, B*5101 and B*5701
associated with higher Gag responses, whereas B*0801
and B*4501 associated with lower responses. Together,
these HLA alleles accounted for 13.6% of the observed
variability. Nested regression models demonstrated that
they can explain most of the association signals detected
in the genome-wide scan.
Conclusion
Genetic variants located in the MHC region strongly asso-
ciate with Gag responses in individuals vaccinated in the
STEP trial. HLA-B alleles known to associate with differ-
ences in HIV-1 control are essential contributors to the
observed signal. This suggests that the host genetic back-
ground modulates individual responses to T cell vaccines
and should be considered in the design and analysis of
future studies.
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